Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

803 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251.
Robbins GK, Cohn SE, Harrison LJ, Smeaton L, Moran L, Rusin D, Dehlinger M, Flynn T, Lammert S, Wu AW, Safren SA, Reynolds NR. Robbins GK, et al. Among authors: flynn t. HIV Clin Trials. 2016 Jul;17(4):165-72. doi: 10.1080/15284336.2016.1189754. HIV Clin Trials. 2016. PMID: 27347650 Free PMC article. Clinical Trial.
Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection.
Addo MM, Draenert R, Rathod A, Verrill CL, Davis BT, Gandhi RT, Robbins GK, Basgoz NO, Stone DR, Cohen DE, Johnston MN, Flynn T, Wurcel AG, Rosenberg ES, Altfeld M, Walker BD. Addo MM, et al. Among authors: flynn t. PLoS One. 2007 Mar 28;2(3):e321. doi: 10.1371/journal.pone.0000321. PLoS One. 2007. PMID: 17389912 Free PMC article.
Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif.
Altfeld MA, Livingston B, Reshamwala N, Nguyen PT, Addo MM, Shea A, Newman M, Fikes J, Sidney J, Wentworth P, Chesnut R, Eldridge RL, Rosenberg ES, Robbins GK, Brander C, Sax PE, Boswell S, Flynn T, Buchbinder S, Goulder PJ, Walker BD, Sette A, Kalams SA. Altfeld MA, et al. Among authors: flynn t. J Virol. 2001 Feb;75(3):1301-11. doi: 10.1128/JVI.75.3.1301-1311.2001. J Virol. 2001. PMID: 11152503 Free PMC article.
Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection.
Rosenberg ES, Graham BS, Chan ES, Bosch RJ, Stocker V, Maenza J, Markowitz M, Little S, Sax PE, Collier AC, Nabel G, Saindon S, Flynn T, Kuritzkes D, Barouch DH; AIDS Clinical Trials Group A5187 Team. Rosenberg ES, et al. Among authors: flynn t. PLoS One. 2010 May 10;5(5):e10555. doi: 10.1371/journal.pone.0010555. PLoS One. 2010. PMID: 20479938 Free PMC article. Clinical Trial.
Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals.
Lichterfeld M, Gandhi RT, Simmons RP, Flynn T, Sbrolla A, Yu XG, Basgoz N, Mui S, Williams K, Streeck H, Burgett-Yandow N, Roy G, Janssens M, Pedneault L, Vandepapelière P, Koutsoukos M, Demoitié MA, Bourguignon P, McNally L, Voss G, Altfeld M. Lichterfeld M, et al. Among authors: flynn t. J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):1-9. doi: 10.1097/QAI.0b013e3182373b77. J Acquir Immune Defic Syndr. 2012. PMID: 21963936 Free PMC article. Clinical Trial.
A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy.
Gandhi RT, O'Neill D, Bosch RJ, Chan ES, Bucy RP, Shopis J, Baglyos L, Adams E, Fox L, Purdue L, Marshak A, Flynn T, Masih R, Schock B, Mildvan D, Schlesinger SJ, Marovich MA, Bhardwaj N, Jacobson JM; AIDS Clinical Trials Group A5130 team. Gandhi RT, et al. Among authors: flynn t. Vaccine. 2009 Oct 9;27(43):6088-94. doi: 10.1016/j.vaccine.2009.05.016. Epub 2009 May 29. Vaccine. 2009. PMID: 19450647 Free PMC article. Clinical Trial.
Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes.
Miura T, Brockman MA, Brumme CJ, Brumme ZL, Carlson JM, Pereyra F, Trocha A, Addo MM, Block BL, Rothchild AC, Baker BM, Flynn T, Schneidewind A, Li B, Wang YE, Heckerman D, Allen TM, Walker BD. Miura T, et al. Among authors: flynn t. J Virol. 2008 Sep;82(17):8422-30. doi: 10.1128/JVI.00535-08. Epub 2008 Jun 18. J Virol. 2008. PMID: 18562530 Free PMC article.
803 results